A Single-center, Randomized, Blinded, Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in Single and Repeat Doses, With and Without Food, in Healthy Male Subjects
Latest Information Update: 22 Oct 2023
At a glance
- Drugs GSK 2849466 (Primary)
- Indications Cachexia; Heart failure
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 02 Mar 2015 Status changed from completed to discontinued.
- 10 Apr 2014 New trial record